Free Trial

OS Therapies (OSTX) Competitors

OS Therapies logo
$1.62 -0.11 (-6.36%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.64 +0.01 (+0.93%)
As of 09:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OSTX vs. CRDF, MDWD, EPRX, SOPH, INBX, YMAB, ACIU, VOR, SCPH, and IMAB

Should you be buying OS Therapies stock or one of its competitors? The main competitors of OS Therapies include Cardiff Oncology (CRDF), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), SOPHiA GENETICS (SOPH), Inhibrx Biosciences (INBX), Y-mAbs Therapeutics (YMAB), AC Immune (ACIU), Vor Biopharma (VOR), scPharmaceuticals (SCPH), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry.

OS Therapies vs. Its Competitors

Cardiff Oncology (NASDAQ:CRDF) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

16.3% of Cardiff Oncology shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 13.8% of OS Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

OS Therapies has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. OS Therapies' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-8,308.50% -76.45% -62.85%
OS Therapies N/A N/A -569.57%

Cardiff Oncology presently has a consensus price target of $11.70, indicating a potential upside of 196.95%. OS Therapies has a consensus price target of $18.00, indicating a potential upside of 1,011.11%. Given OS Therapies' stronger consensus rating and higher probable upside, analysts plainly believe OS Therapies is more favorable than Cardiff Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
OS Therapies
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
3.40

In the previous week, Cardiff Oncology had 2 more articles in the media than OS Therapies. MarketBeat recorded 6 mentions for Cardiff Oncology and 4 mentions for OS Therapies. Cardiff Oncology's average media sentiment score of 0.72 beat OS Therapies' score of 0.17 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OS Therapies
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

OS Therapies has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than OS Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$680K385.48-$45.43M-$0.92-4.28
OS TherapiesN/AN/A-$7.79M-$0.86-1.88

Summary

OS Therapies beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks.

Get OS Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OSTX vs. The Competition

MetricOS TherapiesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$48.61M$820.66M$5.50B$20.52B
Dividend YieldN/A4.84%5.25%3.78%
P/E Ratio-1.881.0926.9727.79
Price / SalesN/A230.52426.0240.34
Price / CashN/A23.4436.8222.26
Price / BookN/A6.137.984.58
Net Income-$7.79M-$27.85M$3.16B$982.91M
7 Day Performance-15.18%0.67%2.36%0.41%
1 Month Performance-18.18%8.48%2.15%3.59%
1 Year PerformanceN/A6.72%33.78%14.47%

OS Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OSTX
OS Therapies
2.7865 of 5 stars
$1.62
-6.4%
$18.00
+1,011.1%
N/A$48.61MN/A-1.88N/A
CRDF
Cardiff Oncology
1.6864 of 5 stars
$3.15
flat
$9.88
+213.5%
+77.5%$209.57M$680K-3.4220News Coverage
Analyst Forecast
MDWD
MediWound
1.619 of 5 stars
$19.37
+0.6%
$31.80
+64.2%
+0.1%$209.39M$20.22M-9.2780
EPRX
Eupraxia Pharmaceuticals
2.3829 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+123.6%$207.13MN/A-7.5829News Coverage
Gap Up
High Trading Volume
SOPH
SOPHiA GENETICS
2.3499 of 5 stars
$3.10
+0.3%
$7.00
+125.8%
-21.2%$206.74M$65.17M-3.10520News Coverage
Positive News
INBX
Inhibrx Biosciences
0.9893 of 5 stars
$14.27
-1.1%
N/A+46.5%$206.63M$200K0.12166News Coverage
YMAB
Y-mAbs Therapeutics
3.2789 of 5 stars
$4.51
-4.0%
$15.60
+245.9%
-62.7%$204.21M$87.68M-7.05150
ACIU
AC Immune
2.7562 of 5 stars
$2.03
+1.0%
$12.00
+491.1%
-40.5%$203.83M$28.30M-3.50140
VOR
Vor Biopharma
3.9425 of 5 stars
$1.62
+52.8%
$5.63
+247.4%
+164.9%$202.44MN/A-0.98140Options Volume
Gap Up
High Trading Volume
SCPH
scPharmaceuticals
4.1364 of 5 stars
$3.81
-1.6%
$14.00
+267.5%
-9.4%$201.14M$41.98M-1.9930
IMAB
I-Mab
2.7279 of 5 stars
$2.42
-5.8%
$6.00
+147.9%
+41.0%$197.62M$3.89M0.00380Gap Up

Related Companies and Tools


This page (NYSE:OSTX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners